The pathways that were enriched in both groups were: breast cancer; platinum drug resistance; ErbB signaling pathway; Rap1 signaling pathway; FoxO signaling pathway; TGF-beta signaling pathway; proteoglycans in cancer; cAMP signaling pathway; p53 signaling pathway; and Ras signaling pathway. This evidence concerns the gene EGFR and breast carcinoma.